ArticleThe Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases
Hospitalization costs of patients with severe acute respiratory infections due to COVID-19 in a public teaching hospital: a micro-costing approach.
Article in The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo estimate the costs associated with the hospitalization of patients with Severe Acute Respiratory Infection (SARI) due to SARS-CoV-2 in a university hospital affiliated with the Brazilian Unified Health System (SUS) in 2020 and 2021.
methodsA bottom-up micro-costing approach was used to conduct a cost analysis based on data from a hospital clinical cohort. Patients with confirmed diagnoses of COVID-19 and SARI, admitted to general wards or intensive care units (with or without mechanical ventilation), were included. Healthcare activities were categorized as hospitalization, ventilation, hemodialysis, nutrition, medications, and laboratory tests. Costs were calculated based on individualized consumption of supplies and procedures, also considering the annualized cost of equipment. Comparisons were made between micro-costing and macro-costing (based on the Hospital Admission Authorizations - AIH).
resultsA total of 627 patients were analyzed. The total cost was R$ 5,824,366.73 (Int$ 2,307,593.80) when healthcare professionals were excluded and R$19,437,731.25 (Int$ 7,701,161.35) when they were included. Medications accounted for the largest share (52.79%). Micro-costing was 1.7-times higher than macro-costing for hospital costs alone and 2.3-times higher when professional costs were included. Multivariate analysis identified length of hospital stay as the main factor associated with increased costs, while age, sex, and referral origin showed no significant association.
conclusionThis study reveals the substantial economic impact of COVID-19-related hospitalizations in high-complexity care settings. It also highlights the importance of improving financing models for the SUS, particularly given the discrepancies between actual costs and federal reimbursement values. These findings contribute to the development of public policies and response strategies for future health emergencies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.